We are live on
!
Find out more
TCM
TCG Crossover Management Portfolio holdings
AUM
$3.5B
1-Year Est. Return
1,165.83%
This Fund
S&P 500
This Quarter
Est. Return
-20.68%
1 Year Est. Return
+1,165.83%
3 Year Est. Return
+3,168.76%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$290M
(-28%)
Cap. Flow
-$4.65M
Cap. Flow
% of AUM
-0.63%
Top 10 Holdings %
Top 10 Hldgs %
55.3%
Holding
38
New
–
Increased
2
Reduced
3
Closed
1
Top Buys
| 1 |
Tyra Biosciences
TYRA
|
+$11.8M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$4.63M |
Top Sells
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$13.4M |
| 2 |
Keros Therapeutics
KROS
|
+$6.39M |
| 3 |
Disc Medicine
IRON
|
+$1.21M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$55.4K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$6.13B
| $89.9M | 12.26% |
3,670,206
| – | – |
|
2
Cogent Biosciences
COGT
$6.48B
| $41.7M | 5.69% |
6,964,375
| – | – |
|
|
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
| $41.6M | 5.67% |
2,890,816
| – | – |
|
4
Mineralys Therapeutics
MLYS
$2.39B
| $39.2M | 5.35% |
2,470,265
| – | – |
|
5
Ocular Therapeutix
OCUL
$2.01B
| $39M | 5.32% |
5,319,148
| – | – |
|
|
ABVX
6
Abivax
ABVX
$12B
| $37.9M | 5.16% |
6,056,596
| – | – |
|
7
Savara
SVRA
$1.13B
| $34.2M | 4.67% |
12,362,205
| – | – |
|
8
Dyne Therapeutics
DYN
$3.76B
| $27.7M | 3.78% |
2,650,150
| – | – |
|
9
Dianthus Therapeutics
DNTH
$5.21B
| $27.2M | 3.72% |
1,501,624
| – | – |
|
|
10
Tyra Biosciences
TYRA
$1.88B
| $27M | 3.68% |
2,898,103
+909,000
| +46% | +$11.8M |
|
11
Xencor
XNCR
$1.11B
| $26.1M | 3.56% |
2,452,138
| – | – |
|
|
12
Disc Medicine
IRON
$2.81B
| $23.1M | 3.15% |
465,257
-21,700
| -4% | -$1.21M |
|
|
TRML
13
DELISTED
Tourmaline Bio
TRML
| $22.5M | 3.07% |
1,477,593
| – | – |
|
|
CDTX
14
DELISTED
Cidara Therapeutics
CDTX
| $21.7M | 2.96% |
1,005,901
| – | – |
|
|
15
Amylyx Pharmaceuticals
AMLX
$1.89B
| $21M | 2.87% |
5,943,812
+1,300,000
| +28% | +$4.63M |
|
|
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
| $19.6M | 2.68% |
275,000
-275,000
| -50% | -$13.4M |
|
17
EyePoint Inc
EYPT
$1.09B
| $19.4M | 2.64% |
3,572,335
| – | – |
|
18
Structure Therapeutics
GPCR
$3.27B
| $18.4M | 2.51% |
1,063,000
| – | – |
|
|
UPB
19
Upstream Bio Inc
UPB
$393M
| $17.1M | 2.34% |
2,801,763
| – | – |
|
|
RAPT
20
DELISTED
RAPT Therapeutics
RAPT
| $16M | 2.18% |
1,636,275
-5,633
| -0.3% | -$55.4K |
|
21
Fulcrum Therapeutics
FULC
$233M
| $15.1M | 2.06% |
5,250,000
| – | – |
|
|
ATXS
22
DELISTED
Astria Therapeutics
ATXS
| $14.7M | 2.01% |
2,761,861
| – | – |
|
23
Tango Therapeutics
TNGX
$4.5B
| $14.7M | 2.01% |
10,736,000
| – | – |
|
|
CMPS
24
Compass Pathways
CMPS
$1.68B
| $11M | 1.51% |
3,858,000
| – | – |
|
25
Kura Oncology
KURA
$967M
| $9.4M | 1.28% |
1,423,642
| – | – |
|
Similar funds
DILIC
IIM
KCM
ACM
BCP
AL
ACA
MSC